Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Infections, Bacterial
Interventions: Gepotidacin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Critically Ill, Hypoglycemia
Interventions: Glucagon-Like Peptide-1, Saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epilepsy, Lennox-Gastaut Syndrome
Interventions: GWP42003-P 20 mg/kg/day Dose, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 55 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 17
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more

Conditions: Dry Eye, Neuropathic Eye Pain, Ocular Microbiome, Depression, Anxiety
Interventions: Azithromycin Oral Product, Placebo Oral; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
Interventions: Azithromycin Injection, Placebo, Standard of Care Preoperative antibiotics; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Conditions: Chronic Hepatitis C Virus Infection
Interventions: ABT-333, Placebo for ABT-333, Pegylated interferon, Ribavirin; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 7
States / cities: Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo; Drug
Lead sponsor: Bicara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 41 more

Conditions: Restless Legs Syndrome (RLS)
Interventions: gabapentin enacarbil, diphenhydramine, placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Vulvovaginal Candidiasis
Interventions: MGCD290; Drug
Lead sponsor: MethylGene Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 19
States / cities: Birmingham, Alabama • San Diego, California • Lake Worth, Florida + 16 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Halobetasol Propionate Lotion 0.05%, Placebo; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: San Diego, California • Fridley, Minnesota • Austin, Texas

Conditions: Shivering, Nausea and Vomiting, Postoperative
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cannabis Dependence, Marijuana Dependence
Interventions: Nabilone, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Interventions: Placebo, Enicepatide; Drug
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more

Conditions: Aging, Frail Older Adults
Interventions: CP-424,391; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 84 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 12
States / cities: Palo Alto, California • San Diego, California • Hamden, Connecticut + 9 more

Conditions: Healthy, Vitamin D Deficiency
Interventions: ergocalciferol, placebo pill; Dietary Supplement · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 9 Years to 18 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Erectile Dysfunction
Interventions: Nebivolol, Sugar Pill; Drug
Lead sponsor: Martin M. Miner, MD; Other
Eligibility: 25 Years to 65 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Providence, Rhode Island

Conditions: Influenza, Human
Interventions: Seasonal LAIV, Placebo, Wild-type A/California/2009-like Influenza Virus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Rochester, New York

Conditions: AKI, CHD - Congenital Heart Disease, Surgery
Interventions: Nitric Oxide, Oxygen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day to 31 Days
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions: NAC 900mg/day, NAC 3600mg/day, NAC 0mg/day (Placebo); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Blinded drug dose conditions; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Device Latency
Interventions: Placebo, Combination product of Aripiprazole + IEM + Sensor + MIND1 Application; Drug · Combination Product
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Long COVID
Interventions: Tonabersat, Placebo; Drug
Lead sponsor: Inflammx Therapeutics Inc; Industry
Eligibility: 21 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Neoplasms, Squamous Cell
Interventions: Gefitinib (Iressa), cisplatin, radiotherapy; Drug · Radiation
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Aurora, Colorado • Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: R228060, Placebo and Paroxetine; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Titusville, New Jersey

Search by objective public record fields.

Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Azithromycin for Meibomian Gland Disease

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Dexmedetomidine After Cesarean for the Treatment of Nausea and Shivering

Nabilone for Cannabis Dependence: A Pilot Study

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults

Vitamin D Deficiency in Adolescent Girls

Nebivolol Effects on Endothelial Function and Erectile Function

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

NO During CPB in Neonates to Reduce Risk of AKI

Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Effects of Dietary Conditions on Drug Response

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder